The continuing challenges of leprosy

Clinical Microbiology Reviews

Volumn 19, Issue 2, 2006, Pages 338-381

  Scollard, D M ^a   Adams, L B ^a   Gillis, T P ^a   Krahenbuhl, J L ^a   Truman, R W ^a   Williams, D L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMETABOLITE; AZATHIOPRINE; BCG VACCINE; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 INHIBITOR; LEPROMIN; LEPROSY VACCINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; PEFLOXACIN; PENTOXIFYLLINE; PROTEOME; RIFAMPICIN; THALIDOMIDE; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN PRESENTING CELL; ARMADILLO; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DENDRITIC CELL; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DISEASE MODEL; ERYTHEMA NODOSUM LEPROSUM; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LEPROMIN TEST; LEPROSY; MYCOBACTERIUM LEPRAE; NERVE INJURY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; RELAPSE; REVERSAL REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENETIC PREDISPOSITION TO DISEASE; GENOME, BACTERIAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; LEPROSTATIC AGENTS; LEPROSY; MICE; MYCOBACTERIUM LEPRAE; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMERASE CHAIN REACTION; SCHWANN CELLS;

ARMADILLO; BACTERIA (MICROORGANISMS); MYCOBACTERIUM LEPRAE;

EID: 33646232950     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.19.2.338-381.2006     Document Type: Review

References (459)

1. Abel, L., and F. Demenais. 1988. Detection of major genes for susceptibility to leprosy and its subtypes in a Caribbean island: Desirade Island. Am. J. Hum. Genet. 42:256-266.
2. Abel, L., F. O. Sanchez, J. Oberti, N. V. Thuc, L. V. Hoa, V. D. Lap, E. Skamene, P. H. Lagrange, and E. Schurr. 1998. Susceptibility to leprosy is linked to the human NRAMP1 gene. J. Infect. Dis. 177:133-145.
3. Adams, L. B., M. C. Dinauer, D. E. Morgenstern, and J. L. Krahenbuhl. 1997. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tubercle Lung Dis. 78:237-246.
4. Adams, L. B., S. G. Franzblau, Z. Vavrin, J. B. Hibbs, Jr., and J. L. Krahenbuhl. 1991. L-Arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J. Immunol. 147:1642-1646.
5. Adams, L. B., Y. Fukutomi, and J. L. Krahenbuhl. 1993. Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence. Infect. Immun. 61:4173-4181.
6. Adams, L. B., C. K. Job, and J. L. Krahenbuhl. 2000. Role of inducible nitric oxide synthase in resistance to Mycobacterium leprae infection in mice. Infect. Immun. 68:5462-5465.
7. Adams, L. B., D. M. Scollard, N. A. Ray, A. M. Cooper, A. A. Frank, I. M. Orme, and J. L. Krahenbuhl. 2002. The study of Mycobacterium leprae infection in interferon-γ gene-disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J. Infect. Dis. 185:S1-S8.
8. Alcais, A., F. O. Sanchez, N. V. Thuc, V. D. Lap, J. Oberti, P. H. Lagrange, E. Schurr, and L. Abel. 2000. Granulomatous reaction to intradermal injection of lepromin (Mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J. Infect. Dis. 181:302-308.
9. Allavena, P., M. Chieppa, P. Monti, and L. Piemonti. 2004. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit. Rev. Immunol. 24:179-192.
10. Allegra, C. J., D. Boarman, J. A. Kovacs, P. Morrison, J. Beaver, B. A. Chabner, and H. Masur. 1990. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J. Clin. Investig. 85:371-379.
11. Alves, L., L. de Mendonca Lima, E. da Silva Maeda, L. Carvalho, J. Holy, E. N. Sarno, M. C. Pessolani, and L. P. Barker. 2004. Mycobacterium leprae infection of human Schwann cells depends on selective host kinases and pathogen-modulated endocytic pathways. FEMS Microbiol. Lett. 238:429-437.
12. Andersson, A. K., M. Chaduvula, S. E. Atkinson, S. Khanolkar-Young, S. Jain, L. Suneetha, S. Suneetha, and D. N. Lockwood. 2005. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect. Immun. 73:3725-3733.
13. Andrade, V. L., J. C. Avelleira, A. Marques, and F. R. Vianna. 1991. Leprosy as cause of false positive results in serological assays for the detection of antibodies to HIV-1. Int. J. Lepr. Other Mycobact. Dis. 59:125-126.
14. Anthony, L. S. D., D. Chatterjee, P. Brennan, and F. E. Nano. 1994. Lipoarabinomannan from Mycobacterium tuberculosis modulates the generation of reactive nitrogen intermediates by gamma interferon-activated macrophages. FEMS Immunol. Med. Microbiol. 8:299-306.
15. Antunes, A., J. Nina, and S. David. 2002. Serological screening for tuberculosis in the community: an evaluation of the Mycodot procedure in an African population with high HIV-2 prevalence (Republic of Guinea-Bissau). Res. Microbiol. 153:301-305.
16. Arnoldi, J., J. Gerdes, and H.-D. Flad. 1990. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am. J. Pathol. 137:749-753.
17. Arnoldi, J., C. Schluter, M. Duchrow, L. Hubner, M. Ernst, A. Teske, H. D. Flad, J. Gerdes, and E. C. Bottger. 1992. Species-specific assessment of Mycobacterium leprae in skin biopsies by in situ hybridization and polymerase chain reaction. Lab. Investig. 66:618-623.
18. Arunthathi, S., L. Ebenezer, and C. Kumuda. 1998. Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Lepr. Rev. 69:173-177.
19. Aseffa, A., M. A. Dietrich, and E. J. Shannon. 1997. Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Immunopharmacol. Immunotoxicol. 19:313-326.
20. Astarie-Dequeker, C., E.-N. N'Diaye, V. Le Cabec, M. G. Rittig, J. Prandi, and I. Mariconneau-Parini. 1999. The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect. Immun. 67:469-477.
21. Atkinson, S. E., S. Khanolkar-Young, S. Marlowe, S. Jain, R. G. Reddy, S. Suneetha, and D. N. Lockwood. 2004. Detection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 (T1R) reactions. Int. J. Lepr. Other Mycobact. Dis. 72:27-34.
22. Azouaou, N., R. H. Gelber, K. Abel, D. T. Sasaki, L. P. Murray, R. M. Locksley, and N. Mohagheghpour. 1993. Reconstitution of Mycobacterium leprae immunity in severe combined immunodeficient mice using a T-cell line. Int. J. Lepr. Other Mycobact. Dis. 61:398-405.
23. Bagshawe, A., G. C. Scott, D. A. Russell, S. C. Wigley, A. Merianos, and G. Berry. 1989. BCG vaccination in leprosy: final results of the trial in Karimui. Papua New Guinea, 1963-79. Bull. W. H. O. 67:389-399.
24. Bakker, M. J. 2005. Epidemiology and prevention of leprosy: a cohort study in Indonesia. Ph.D. thesis. KIT Biomedical Research, Amsterdam, The Netherlands.
25. Barnes, P. F., D. Chatterjee, J. S. Abrams, S. Lu, E. Wang, M. Yamamura, P. J. Brennan, and R. L. Modlin. 1992. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan: relationship to chemical structure. J. Immunol. 149:541.
26. Barnes, P. F., D. Chatterjee, P. J. Brennan, T. H. Rea, and R. L. Modlin. 1992. Tumor necrosis factor production in patients with leprosy. Infect. Immun. 60:1441-1446.
27. Barnetson, R. S., G. Bjune, J. M. Pearson, and G. Kronvall. 1976. Cell mediated and humoral immunity in "reversal reactions." Int. J. Lepr. Other Mycobact. Dis. 44:267-274.
28. Barshes, N. R., S. E. Goodpastor, and J. A. Goss. 2004. Pharmacologic immunosuppression. Front. Biosci. 9:411-420.
29. Becx-Bleumink, M., and D. Berhe. 1992. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int. J. Lepr. Other Mycobact. Dis. 60:173-184.
30. Bedi, B. M., E. B. Harris, E. Narayanan, and W. F. Kirchheimer. 1976. Delayed hypersensitivity tests with Mycobacterium leprae purified protein derivative. Lepr. India 48:8-18.
31. Beiguelman, B., and R. Quagliato. 1965. Nature and familial character of the lepromin reactions. Int. J. Lepr. Other Mycobact. Dis. 33:800-807.
32. Belliappa, A. D., R. M. Bhat, and J. Martis. 2002. Leprosy in type I reaction and diabetes mellitus in a patient with HIV infection. Int. J. Dermatol. 41:694-695.
33. Beyene, D., A. Aseffa, M. Harboe, D. Kidane, M. Macdonald, P. R. Klatser, G. A. Bjune, and W. C. Smith. 2003. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village. Ethiopia. Epidemiol. Infect. 131:841-848.
34. Blackwell, J. M., S. Searle, T. Goswami, and E. N. Miller. 2000. Understanding the multiple functions of Nramp1. Microbes Infect. 2:317-321.
35. Blum, L., B. Flageul, S. Sow, P. Launois, M. D. Vignon-Pennamen, A. Coll, and J. Millan. 1993. Leprosy reversal reaction in HIV-positive patients. Int. J. Lepr. Other Mycobact. Dis. 61:214-217.
36. Bochud, P. Y., T. R. Hawn, and A. Aderem. 2003. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170:3451-3454.
37. Brandt, L., Y. A. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, S. G. Reed, and I. M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mfb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72:6622-6632.
38. Brennan, P. J. 2000. Skin test development in leprosy: progress with first-generation skin test antigens, and an approach to the second generation. Lepr. Rev. 71(Suppl.):S50-S54.
39. Brennan, P. J., and V. D. Vissa. 2001. Genomic evidence for the retention of the essential mycobacterial cell wall in the otherwise defective Mycobacterium leprae. Lepr. Rev. 72:415-428.
40. Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. B. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736.
41. Britton, W. J. 1998. The management of leprosy reversal reactions. Lepr. Rev. 69:225-234.
42. Britton, W. J., L. Hellqvist, A. Basten, and R. L. Raison. 1985. Mycobacterium leprae antigens involved in human immune responses. I. Identification of four antigens by monoclonal antibodies. J. Immunol. 135:4171-4177.
43. Britton, W. J., and D. N. Lockwood. 2004. Leprosy. Lancet 363:1209-1219.
44. Brosch, R., S. V. Gordon, K. Eiglmeier, T. Gamier, and S. T. Cole. 2000. Comparative genomics of the leprosy and tubercle bacilli. Res. Microbiol. 151:135-142.
45. Browne, S. G., and L. M. Hogerzeil. 1962. "B 663" in the treatment of leprosy. Preliminary report of a pilot trial. Lepr. Rev. 33:6-10.
46. Bruce, S., T. L. Schroeder, K. Ellner, H. Rubin, T. Williams, and J. E. Wolf, Jr. 2000. Armadillo exposure and Hansen's disease: an epidemiologic survey in southern Texas. J. Am. Acad. Dermatol. 43:223-228.
47. Buhrer, S. S., H. L. Smits, G. C. Gussenhoven, C. W. van Ingen, and P. R. Klatser. 1998. A simple dipstick assay for the detection of antibodies to phenolic glycolipid-1 of Mycobacterium leprae. Am. J. Trop. Med. Hyg. 58:133-136.
48. Burdick, A. A., and C. C. Ramirez. 2005. The role of mycophenolate mofetil in the treatment of leprosy reactions. Int. J. Lepr. Other Mycobact. Infect. 73:127-128.
49. Buschman, E., and E. Skamene. 2004. Linkage of leprosy susceptibility to Parkinson's disease genes. Int. J. Lepr. Other Mycobact. Dis. 72:169-170.
50. Butlin, C. R., K. D. Neupane, S. S. Failbus, A. Morgan, and W. J. Britton. 1996. Drug resistance in Nepali leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 64:136-141.
51. Bwire, R., and H. J. Kawuma. 1994. Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Trans. R Soc. Trop. Med. Hyg. 88:315-316.
52. Cambau, E., P. Bonnafous, E. Perani, W. Sougakoff, B. Ji, and V. Jarlier. 2002. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin. Infect. Dis. 34:39-45.
53. Cambau, E., E. Perani, I. Guillemin, P. Jamet, and B. Ji. 1997. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 349:103-104.
54. Cambau, E., W. Sougakoff, and V. Jarlier. 1994. Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria. FEMS Microbiol. Lett. 116:49-54.
55. Carus, N. H., M. B. Raizman, D. L. Williams, and A. S. Baker. 1995. Relapse of Mycobacterium leprae infection with ocular manifestations. Clin. Infect. Dis. 20:776-780.
56. Cellona, R. V., M. F. Balagon, E. C. dela Cruz, J. A. Burgos, R. M. Abalos, G. P. Walsh, R. Topolski, R. H. Gelber, and D. S. Walsh. 2003. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 71:308-319.
57. Chan, E. S., and B. N. Cronstein. 2002. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4:266-273.
58. Chan, G. P., B. Y. Garcia-Ignacio, V. E. Chavez, J. B. Livelo, C. L. Jimenez, M. L. Parrilla, and S. G. Franzblau. 1994. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob. Agents Chemother. 38:515-517.
59. Chan, J., T. Fujiwara, P. Brennan, M. McNeil, S. J. Turco, J.-C. Sibille, M. Snapper, P. Aisen, and B. R. Bloom. 1989. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc. Natl. Acad. Sci. USA 86:2453-2457.
60. Chatterjee, D., A. D. Roberts, K. Lowell, P. J. Brennan, and I. M. Orme. 1992. Structural basis for the capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect. Immun. 60:1249-1253.
61. Chaudhury, S., S. K. Hazra, B. Saha, B. Mazumder, P. C. Biswas, D. Chattopadhya, and K. Saha. 1994. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis. Int. J. Lepr. Other Mycobact. Dis. 62:389-394.
62. Chehl, S., C. K. Job, and R. C. Hastings. 1985. Transmission of leprosy in nude mice. Am. J. Trop. Med. Hyg. 34:1161-1166.
63. Chemouilli, P., S. Woods, G. Said, and S. T. Cole. 1996. Detection of Mycobacterium leprae in nerve lesions by the polymerase chain reaction. Int. J. Lepr. Other Mycobact. Dis. 64:1-5.
64. Chen, X. S., W. Z. Li, C. Jiang, and G. Y. Ye. 1999. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy. Int. J. Lepr. Other Mycobact. Dis. 67:379-387.
65. Chin-A-Lien, R. A., W. R. Faber, and B. Naafs. 1994. Cyclosporin A treatment in reversal reaction. Trop. Geogr. Med. 46:123-124.
66. + T lymphocytes with cytolytic activity. Infect. Immun. 54:793-797.
67. Chiplunkar, S. V., M. V. Deshmukh, P. D. Samson, R. Butlin, W. S. Bhatki, R. G. Chulawalla, M. G. Deo, and S. G. Gangal. 1990. Natural killer-cell-mediated and antibody-dependent cellular cytotoxicity in leprosy. Int. J. Lepr. Other Mycobact. Dis. 58:334-341.
68. Choudhury, A., N. F. Mistry, and N. H. Antia. 1989. Blocking of Mycobacterium leprae adherence to dissociated Schwann cells by anti-mycobacterial antibodies. Scand. J. Immunol. 30:505-509.
69. Clark-Curtiss, J. E., and M. A. Docherty. 1989. A species-specific repetitive sequence in Mycobacterium leprae DNA. J. Infect. Dis. 159:7-15.
70. Clark-Curtiss, J. E., and G. P. Walsh. 1989. Conservation of genomic sequences among isolates of Mycobacterium leprae. J. Bacteriol. 171:4844-4851.
71. Clements, B., and D. M. Scollard. 1996. Leprosy, p. 9.2-9.28. In C. L. Mandell and R. Fekety (ed.), Atlas of infectious diseases. Current Medicine, Philadelphia, Pa.
72. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
73. Cole, S. T. 1998. Comparative mycobacterial genomics. Curr. Opin. Microbiol. 1:567-571.
74. Cole, S. T., R. Brosch, J. Parkhill, T. Gamier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
75. Cole, S. T., K. Eiglmeier, J. Parkhill, K. D. James, J. R. Thomson, R. P. Wheeler, N. Honore, T. Garnier, C. Churcher, D. Harris, K. Mungall, D. Basham, D. Brown, T. Chillingworth, R. Color, R. M. Davies, K. Devlin, S. Duthoy, T. Feltwell, A. Fraser, N. Hamlin, S. Holroyd, T. Hornsby, A. Fraser, N. Hamlin, S. Holroyd, T. Hornby, K. Jagels, C. Lacroix, J. Maclean, S. Moule, L. Murphy, K. Oliver, M. A. Quail, M. A. Rajandream, K. M. Rutherford, S. Rutter, K. Seeger, S. Simon, M. Simmonds, J. Skelton, R. Squares, S. Squares, K. Stevens, K. Taylor, S. Whitehead, J. R. Woodward, and B. G. Barrell. 2001. Massive gene decay in the leprosy bacillus. Nature 409:1007-1011.
76. Colston, M. J., and G. R. Hilson. 1976. Growth of Mycobacterium leprae and M. marinum in congenially athymic (nude) mice. Nature 262:736-741.
77. Convit, J., C. Sampson, M. Zuniga, P. G. Smith, J. Plata, J. Silva, J. Molina, M. E. Pinardi, B. R. Bloom, and A. Salgado. 1992. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 339:446-450.
78. Couppie, P., S. Abel, H. Voinchet, M. Roussel, R. Helenon, M. Huerre, D. Sainte-Marie, and A. Cabie. 2004. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch. Dermatol. 140:997-1000.
79. Cunha, S. S., L. C. Rodrigues, V. Pedrosa, I. M. Dourado, M. L. Barreto, and S. M. Pereira. 2004. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr. Rev. 75:357-366.
80. Daffe, M., M. McNeil, and P. J. Brennan. 1993. Major structural features of the cell wall arabinogalactans of Mycobacterium, Rhodococcus, and Nocardia spp. Carbohydr Res. 249:383-398.
81. Dallas, W. S., J. E. Gowen, P. H. Ray, M. J. Cox, and I. K. Dev. 1992. Cloning, sequencing, and enhanced expression of the dihydropteroate synthase gene of Escherichia coli MC4100. J. Bacteriol. 174:5961-5970.
82. Davey, T. F., and R. R. Schenck. 1964. The endocrines in leprosy, p. 198. In R. G. Cochrane and T. F. Davey (ed.), Leprosy in theory and practice. John Wright and Sons, Ltd., Bristol, United Kingdom.
83. Dawlah, Z. M., A. Cabrera, K. Ahern, and W. R. Levis. 2002. A phase 2 open trial of pentoxifylline for the treatment of leprosy reactions. Int. J. Lepr. Other Mycobact. Dis. 70:38-43.
84. De Bruyn, E. E., H. C. Steel, E. J. Van Rensburg, and R. Anderson. 1996. The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism. J. Antimicrob. Chemother. 38:349-362.
85. de Carsalade, G. Y., D. Wallach, E. Spindler, J. Pennec, F. Cottenot, and B. Flageul. 1997. Daily multidrug therapy for leprosy: results of a fourteen-year experience. Int. J. Lepr. Other Mycobact. Dis. 65:37-44.
86. Dehio, K. 1952. On the Lepra Anesthetica and the pathogenetic relation of its disease-appearances. Proceedings of the International Scientific Leprosy Conference in Berlin, October 1897. Lepr. India 24:78-83.
87. dela Cruz, E., R. V. Cellona, M. V. Balagon, L. G. Villahermosa, T. T. Fajardo, Jr., R. M. Abalos, E. V. Tan, and G. P. Walsh. 1996. Primary dapsone resistance in Cebu, The Philippines; cause for concern. Int. J. Lepr. Other Mycobact. Dis. 64:253-256.
88. Demangel, C., and W. J. Britton. 2000. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol. Cell Biol. 78:318-324.
89. De Sarkar, A., I. Kaur, B. D. Radotra, and B. Kumar. 2001. Impact of combined Mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 69:187-194.
90. de Vries, R. R., R. F. Fat, L. E. Nijenhuis, and J. J. van Rood. 1976. HLA-linked genetic control of host response to Mycobacterium leprae. Lancet ii:1328-1330.
91. de Wit, M. Y., J. T. Douglas, J. McFadden, and P. R. Klatser. 1993. Polymerase chain reaction for detection of Mycobacterium leprae in nasal swab specimens. J. Clin. Microbiol. 31:502-506.
92. de Wit, M. Y., W. R. Faber, S. R. Krieg, J. T. Douglas, S. B. Lucas, N. Montreewasuwat, S. R. Pattyn, R. Hussain, J. M. Ponnighaus, R. A. Hartskeerl, et al. 1991. Application of a polymerase chain reaction for the detection of Mycobacterium leprae in skin tissues. J. Clin. Microbiol. 29:906-910.
93. de Wit, M. Y., and P. R. Klatser. 1994. Mycobacterium leprae isolates from different sources have identical sequences of the spacer region between the 16S and 23S ribosomal RNA genes. Microbiology 140:1983-1987.
94. Dinauer, M. C., M. B. Deck, and E. R. Unanue. 1997. Mice lacking reduced nicotinamide adenine dinucleotide phosphate oxidase activity show increased susceptibility to early infection with Listeria monocytogenes. J. Immunol. 158:5581-5583.
95. Dockrell, H. M., S. Brahmbhatt, B. D. Robertson, S. Britton, U. Fruth, N. Gebre, M. Hunegnaw, R. Hussain, R. Manadhar, L. Murrillo, M. C. Pessolani, P. Roche, J. L. Salgado, E. Sampaio, F. Shahid, J. E. Thole, and D. B. Young. 2000. Diagnostic assays for leprosy based on T-cell epitopes. Lepr. Rev. 71(Suppl.):S55-59.
96. Dockrell, H. M., S. K. Young, K. Britton, P. J. Brennan, B. Rivoire, M. F. Waters, S. B. Lucas, F. Shahid, M. Dojki, T. J. Chiang, Q. Ehsan, K. P. McAdam, and R. Hussain. 1996. Induction of Th1 cytokine responses by mycobacterial antigens in leprosy. Infect. Immun. 64:4385-4389.
97. Donner, R. S., and J. A. Shively. 1967. The "Lucio phenomenon" in diffuse leprosy. Ann. Intern. Med. 67:831-836.
98. Douglas, J. T., R. V. Celona, R. M. Abalos, M. G. Madarang, and T. Fajardo. 1987. Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, the Philippines. Int. J. Lepr. Other Mycobact. Dis. 55:718-721.
99. Draper, P., O. Kandler, and A. Darbre. 1987. Peptidoglycan and arabinogalactan of Mycobacterium leprae. J. Gen. Microbiol. 133:1187-1194.
100. Drlica, K., C. Xu, J. Y. Wang, R. M. Burger, and M. Malik. 1996. Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob. Agents Chemother. 40:1594-1599.
101. Drosos, A. A., P. J. Brennan, M. S. Elisaf, S. G. Stefanou, C. S. Papadimitriou, and H. M. Moutsopoulos. 1986. Specific antigen and antibody to Mycobacterium leprae in the cryoprecipitate of a patient with Lucio phenomenon. Rheumatol. Int. 6:93-94.
102. Duncan, M. E., J. M. Pearson, D. S. Ridley, R. Melsom, and G. Bjune. 1982. Pregnancy and leprosy: the consequences of alterations of cell-mediated and humoral immunity during pregnancy and lactation. Int. J. Lepr. Other Mycobact. Dis. 50:425-435.
103. Ebenezer, G. J., G. Norman, G. A. Joseph, S. Daniel, and C. K. Job. 2002. Drug resistant Mycobacterium leprae-results of mouse footpad studies from a laboratory in south India. Indian J. Lepr. 74:301-312.
104. Eiglmeier, K., N. Honore, S. A. Woods, B. Caudron, and S. T. Cole. 1993. Use of an ordered cosmid library to deduce the genomic organization of Mycobacterium leprae. Mol. Microbiol. 7:197-206.
105. Eiglmeier, K., J. Parkhill, N. Honore, T. Garnier, F. Tekaia, A. Telenti, P. Klatser, K. D. James, N. R. Thomson, P. R. Wheeler, C. Churcher, D. Harris, K. Mungall, B. G. Barrell, and S. T. Cole. 2001. The decaying genome of Mycobacterium leprae. Lepr. Rev. 72:387-398.
106. Eiglmeier, K., S. Simon, T. Garnier, and S. T. Cole. 2001. The integrated genome map of Mycobacterium leprae. Lepr. Rev. 72:462-469.
107. Fajardo, T. T., Jr., L. G. Villahermosa, E. C. Cruz, R. V. Cellona, M. V. Balagon, R. M. Abalos, and R. H. Gelber. 2004. A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy. Lepr. Rev. 75:389-397.
108. Feitosa, M., H. Krieger, I. Borecki, B. Beiguelman, and D. C. Rao. 1996. Genetic epidemiology of the Mitsuda reaction in leprosy. Hum. Hered. 46:32-35.
109. Ferreira, F. R., L. Z. Goulart, H. D. Silva, and I. M. B. Goulart. 2004. Susceptibility to leprosy may be conditioned by an interaction between NRAMP1 promoter polymorphisms and the lepromin response. Int. J. Lepr. Other Mycobact. Dis. 72:457-467.
110. Fiallo, P., D. L. Williams, G. P. Chan, and T. P. Gillis. 1992. Effects of fixation on polymerase chain reaction detection of Mycobacterium leprae. J. Clin. Microbiol. 30:3095-3098.
111. Filice, G. A., R. N. Greenberg, and D. W. Fraser. 1977. Lack of observed association between armadillo contact and leprosy in humans. Am. J. Trop. Med. Hyg. 26:137-139.
112. Fine, P. E. 2001. BCG: the challenge continues. Scand. J. Infect. Dis. 33:243-245.
113. Fine, P. E. M., and R. W. Truman. 1998. Report of the workshop on epidemiology, transmission and vaccines in leprosy. Int. J. Lepr. Other Mycobact. Dis. 66:596-597.
114. Flad, H. D., J. Arnoldi, A. Ohlert, J. Kazda, and J. Gerdes. 1990. Cytokine production and proliferative capacity of infiltrating cells in various forms of leprosy. Trop. Med. Parasitol. 41:307-309.
115. Fleischmann, R. D., D. Alland, J. A. Eisen, L. Carpenter, O. White, J. Peterson, R. DeBoy, R. Dodson, M. Gwinn, D. Haft, E. Hickey, J. F. Kolonay, W. C. Nelson, L. A. Umayam, M. Ermolaeva, S. L. Salzberg, A. Delcher, T. Utterback, J. Weidman, H. Khouri, J. Gill, A. Mikula, W. Bishai, W. R. Jacobs, Jr., J. C. Venter, and C. M. Fraser. 2002. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184:5479-5490.
116. Foss, N. T., E. B. de Oliveira, and C. L. Silva. 1993. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int. J. Lepr. Other Mycobact. Dis. 61:218-226.
117. Frankel, R. I., R. T. Mita, R. Kim, and F. J. Dann. 1992. Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine. Int. J. Lepr. Other Mycobact. Dis. 60:8-12.
118. Franzblau, S. G. 1989. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob. Agents Chemother. 33:2115-2117.
119. Franzblau, S. G., and K. E. White. 1990. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrob. Agents Chemother. 34:229-231.
120. Fsihi, H., and S. T. Cole. 1995. The Mycobacterium leprae genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel polA locus associated with genomic variability. Mol. Microbiol. 16:909-919.
121. Fsihi, H., V. Vincent, and S. T. Cole. 1996. Homing events in the gyrA gene of some mycobacteria. Proc. Natl. Acad. Sci. USA 93:3410-3415.
122. Fujita, M., Y. Miyachi, S. Izumi, H. Ishida, A. Obara, and S. Imamura. 1991. Immunohistochemical study of lepromin reaction in healthy adults. J. Dermatol Sci. 2:179-182.
123. Fukutomi, Y. 2004. Functional changes of macrophages in Hansen's disease. Nihon Hansenbyo Gakkai Zasshi 73:253-261. (In Japanese.)
124. Garcia, V. E., K. Uyemura, P. A. Sieling, M. T. Ochoa, C. T. Morita, H. Okamura, M. Kurimoto, T. H. Rea, and R. L. Modlin. 1999. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J. Immunol. 162:6114-6121.
125. Gebre, S., P. Saunderson, T. Messele, and P. Byass. 2000. The effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia. Lepr. Rev. 71:338-343.
126. Geijtenbeek, T. B., S. J. Van Vliet, E. A. Koppel, M. Sanchez-Hernandez, C. M. Vandenbroucke-Grauls, B. Appelmelk, and Y. Van Kooyk. 2003. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197:7-17.
127. Gelber, R. H. 1987. Activity of minocycline in Mycobacterium leprae-infected mice. J. Infect. Dis. 156:236-239.
128. Gelber, R. H. 1995. Successful treatment of a lepromatous patient with clarithromycin. Int. J. Lepr. Other Mycobact. Dis. 63:113-115.
129. Gelber, R. H., V. F. Balagon, and R. V. Cellona. 2004. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int. J. Lepr. Other Mycobact. Dis. 72:493-500.
130. Gelber, R. H., A. Iranmanesh, L. Murray, P. Siu, and M. Tsang. 1992. Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob. Agents Chemother. 36:2544-2547.
131. Gerlach, W. 1891. Investigations on anaesthetic skin patches. Virchows Arch. 125:126-145.
132. Gillis, T. P., and T. M. Buchanan. 1982. Production and partial characterization of monoclonal antibodies to Mycobacterium leprae. Infect. Immun. 37:172-178.
133. Gillis, T. P., and D. L. Williams. 1991. Polymerase chain reaction and leprosy. Int. J. Lepr. Other Mycobact. Dis. 59:311-316.
134. Gimenez, M. F., I. Gigli, and F. A. Tausk. 1989. Differential expression of Langerhans cells in the epidermis of patients with leprosy. Br. J. Dermatol. 121:19-26.
135. Girdhar, B. K., A. Girdhar, and A. Kumar. 2000. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr. Rev. 71:144-153.
136. Godal, T., B. Myrvang, D. R. Samuel, W. F. Ross, and M. Lofgren. 1973. Mechanism of "reactions" in borderline tuberculoid (BT) leprosy. A preliminary report. Acta Pathol. Microbiol. Scand. A 236:45-53.
137. Goodless, D. R., A. L. Viciana, R. J. Pardo, and P. Ruiz. 1994. Borderline tuberculoid Hansen's disease in AIDS. J. Am. Acad. Dermatol. 30:866-869.
138. Grosset, J. H., C. C. Guelpa-Lauras, P. Bobin, G. Brucker, J. L. Cartel, M. Constant-Desportes, B. Flageul, M. Frederic, J. C. Guillaume, and J. Millan. 1989. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int. J. Lepr. Other Mycobact. Dis. 57:607-614.
139. Grosset, J. H., B. H. Ji, C. C. Guelpa-Lauras, E. G. Perani, and L. N. N'Deli. 1990. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 58:281-295.
140. Gruenheid, S., and P. Gros. 2000. Genetic susceptibility to intracellular infections: Nramp1, macrophage function and divalent cations transport. Curr. Opin. Microbiol. 3:43-48.
141. Gupte, M. D., R. S. Vallishayee, D. S. Anantharaman, B. Nagaraju, Sreevatsa, S. Balasubramanyam, R. L. de Britto, N. Elango, N. Uthayakumaran, V. N. Mahalingam, G. Lourdusamy, A. Ramalingam, S. Kannan, and J. Arokiasamy. 1998. Comparative leprosy vaccine trial in south India. Indian J. Lepr. 70:369-388.
142. Haanen, J. B., R. de Waal Malefijt, P. C. Res, E. M. Kraakman, T. H. Ottenhoff, R. R. de Vries, and H. Spits. 1991. Selection of a human T helper type 1-like T cell subset by mycobacteria. J. Exp. Med. 174:583-592.
143. Haanpaa, M., D. N. Lockwood, and A. Hietaharju. 2004. Neuropathic pain in leprosy. Lepr. Rev. 75:7-18.
144. Hackel, C., S. Houard, F. Portaels, A. van Eisen, A. Herzog, and A. Bollen. 1990. Specific identification of Mycobacterium leprae by the polymerase chain reaction. Mol. Cell. Probes 4:205-210.
145. Hagge, D., S. O. Robinson, D. Scollard, G. McCormick, and D. L. Williams. 2002. A new model for studying the effects of Mycobacterium leprae on Schwann cell and neuron interactions. J. Infect. Dis. 186:1283-1296.
146. Hagge, D. A., N. A. Ray, J. L. Krahenbuhl, and L. B. Adams. 2004. An in vitro model for the lepromatous leprosy granuloma: fate of Mycobacterium leprae from target macrophages after interaction with normal and activated effector macrophages. J. Immunol. 172:7771-7779.
147. Haile, Y., and J. J. Ryon. 2004. Colorimetric microtitre plate hybridization assay for the detection of Mycobacterium leprae 16S rRNA in clinical specimens. Lepr. Rev. 75:40-49.
148. Halloran, P. F. 2004. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351:2715-2729.
149. Hamerlinck, F. F., P. R. Klatser, D. S. Walsh, J. D. Bos, G. P. Walsh, and W. R. Faber. 1999. Serum neopterin as a marker for reactional states in leprosy. FEMS Immunol. Med. Microbiol. 24:405-409.
150. Hancock, G. E., A. Molloy, B. K. Ab, R. Kiessling, M. Becx-Bleumink, Z. A. Cohn, and G. Kaplan. 1991. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. Cell. Immunol. 132:277-284.
151. Hartskeerl, R. A., M. Y. de Wit, and P. R. Klatser. 1989. Polymerase chain reaction for the detection of Mycobacterium leprae. J. Gen. Microbiol. 135:2357-2364.
152. Hashimoto, K., Y. Maeda, H. Kimura, K. Suzuki, A. Masuda, M. Matsuoka, and M. Makino. 2002. Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function. Infect. Immun. 70:5167-5176.
153. Hatagima, A., D. V. Opromolla, S. Ura, M. F. Feitosa, B. Beiguelman, and H. Krieger. 2001. No evidence of linkage between Mitsuda reaction and the NRAMP1 locus. Int. J. Lepr. Other Mycobact. Dis. 69:99-103.
154. Hayes, C. E., F. E. Nashold, K. M. Spach, and L. B. Pedersen. 2003. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol (Noisy-Le-Grand) 49:277-300.
155. Heine, H., and E. Lien. 2003. Toll-like receptors and their function in innate and adaptive immunity. Int. Arch. Allergy Immunol. 130:180-192.
156. Holzer, T. J., K. E. Nelson, R. G. Crispen, and B. R. Anderson. 1986. Mycobacterium leprae fails to stimulate phagocytic cell superoxide anion generation. Infect. Immun. 51:514-520.
157. Honore, N., and S. T. Cole. 1993. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob. Agents Chemother. 37:414-418.
158. Honore, N., E. Perrani, A. Telenti, J. Grosset, and S. T. Cole. 1993. A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis. 61:600-604.
159. Honore, N., P. W. Roche, J. H. Grosset, and S. T. Cole. 2001. A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr. Rev. 72:441-448.
160. Hori, S., and S. Sakaguchi. 2004. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 6:745-751.
161. Humphres, R. C., R. H. Gelber, and J. L. Krahenbuhl. 1982. Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Clin. Exp. Immunol. 49:500-508.
162. Hunger, R. E., P. A. Sieling, M. T. Ochoa, M. Sugaya, A. E. Burdick, T. H. Rea, P. J. Brennan, J. T. Belisle, A. Blauvelt, S. A. Porcelli, and R. L. Modlin. 2004. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J. Clin. Investig. 113:701-708.
163. Hussain, T., S. Sinha, K. Kulshreshtha, K. Katoch, V. Yadev, U. Sengupta, and V. M. Katoch. 2005. Seroprevalence of HIV infection among leprosy patients in Agra, India: trends and perspective. Int. J. Lepr. Other Mycobact. Infect. 73:93-99.
164. Jacobs, J. M., V. P. Shetty, and N. H. Antia. 1987. Myelin changes in leprous neuropathy. Acta Neuropathol. 74:75-80.
165. Jacobs, J. M., V. P. Shetty, and N. H. Antia. 1987. Teased fibre studies in leprous neuropathy. J. Neurol. Sci. 79:301-313.
166. Jacobs, W. R., M. A. Docherty, R. Curtiss III, and J. E. Clark-Curtiss. 1986. Expression of Mycobacterium leprae genes from a Streptococcus mutans promoter in Escherichia coli K-12. Proc. Natl. Acad. Sci. USA 83:1926-1930.
167. Jacobson, R. R. 1997. Treatment of leprosy, p. 470. In R. C. Hastings (ed.), Leprosy. Chruchill Livingstone, Edinburgh, Scotland.
168. Jacobson, R. R., and J. L. Krahenbuhl. 1999. Leprosy. Lancet 353:655-660.
169. Jamet, P., B. Ji, et al. 1995. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Int. J. Lepr. Other Mycobact. Dis. 63:195-201.
170. Jamet, P., I. Traore, J. A. Husser, and B. Ji. 1992. Short-term trial of clofazimine in previously untreated lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 60:542-548.
171. Jamil, S., S. M. Wilson, M. Hacket, R. Hussain, and N. G. Stoker. 1994. A colorimetric PCR method for the detection of M. leprae in skin biopsies from leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 62:512-520.
172. Ji, B. 1998. Treatment of leprosy, p. 398-424. In P. R. Gangadharam and P. A. Jenkins (ed.), Mycobacteria, vol. II: chemotherapy. International Thomson Publishing Co., New York, N.Y.
173. Ji, B., and J. Grosset. 1991. Ofloxacin for the treatment of leprosy. Acta Leprol. 7:321-326.
174. Ji, B., P. Jamet, E. G. Perani, P. Bobin, and J. H. Grosset. 1993. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J. Infect. Dis. 168:188-190.
175. Ji, B., P. Jamet, E. G. Perani, S. Sow, C. Lienhardt, C. Petinon, and J. H. Grosset. 1996. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob. Agents Chemother. 40:2137-2141.
176. Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. H. Grosset. 1994. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob. Agents Chemother. 38:662-667.
177. Ji, B., S. Sow, E. Perani, C. Lienhardt, V. Diderot, and J. Grosset. 1998. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob. Agents Chemother. 42:1115-1120.
178. Ji, B. H. 1985. Drug resistance in leprosy-a review. Lepr. Rev. 56:265-278.
179. Jin, D. J., and C. A. Gross. 1988. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 202:45-58.
180. Job, C. K. 1971. Pathology of peripheral nerve lesions in lepromatous leprosy-a light and electron microscopic study. Int. J. Lepr. Other Mycobact. Dis. 39:251-268.
181. Job, C. K. 1989. Nerve damage in leprosy. Int. J. Lepr. Other Mycobact. Dis. 57:532-539.
182. Job, C. K., V. Drain, R. Truman, A. T. Deming, R. M. Sanchez, and R. C. Hastings. 1992. The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies to PGL-1. Indian J. Lepr. 64:137-151.
183. Job, C. K., W. F. Kirchheimer, and R. M. Sanchez. 1982. Tissue response to lepromin, an index of susceptibility of the armadillo to M. leprae infection-a preliminary report. Int. J. Lepr. Other Mycobact. Dis. 50:177-182.
184. Job, C. K., W. F. Kirchheimer, and R. M. Sanchez. 1982. Borderline leprosy in an experimentally infected armadillo. Int. J. Lepr. Other Mycobact. Dis. 50:488-493.
185. Job, C. K., W. F. Kirchheimer, and R. M. Sanchez. 1983. Variable lepromin response to Mycobacterium leprae in resistant armadillos. Int. J. Lepr. Other Mycobact. Dis. 51:347-353.
186. Job, C. K., R. M. Sanchez, and R. C. Hastings. 1985. Manifestations of experimental leprosy in the armadillo. Am. J. Trop. Med. Hyg. 34:151-161.
187. Job, C. K., R. M. Sanchez, and R. C. Hastings. 1991. An attempt to produce experimental tuberculoid leprosy in the nine-banded armadillo. Indian J. Lepr. 63:159-165.
188. Job, C. K., R. M. Sanchez, R. Hunt, and R. C. Hastings. 1987. Prevalence and significance of Mitsuda reaction in the nine-banded armadillo. Int. J. Lepr. Other Mycobact. Dis. 55:685-688.
189. Job, C. K., R. M. Sanchez, R. Hunt, R. W. Truman, and R. C. Hastings. 1993. Armadillos (Dasypus novemcinctus) as a model to test antileprosy vaccines: a preliminary report. Int. J. Lepr. Other Mycobact. Dis. 61:394-397.
190. Job, C. K., and R. W. Truman. 1999. Mitsuda-negative, resistant nine-banded armadillos and enhanced Mitsuda response to live M. leprae [letter]. Int. J. Lepr. Other Mycobact. Dis. 67:475-477.
191. Johnstone, P. A. 1987. The search for animal models of leprosy. Int. J. Lepr. Other Mycobact. Dis. 55:535-547.
192. Kai, M., M. Matsuoka, N. Nakata, S. Maeda, M. Gidoh, Y. Maeda, K. Hashimoto, K. Kobayashi, and Y. Kashiwabara. 1999. Diaminodiphenyl-sulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol. Lett. 177:231-235.
193. Kaleab, B., T. Ottenoff, P. Converse, E. Halapi, G. Tadesse, M. Rottenberg, and R. Kiessling. 1990. Mycobacterial-induced cytotoxic T cells as well as nonspecific killer cells derived from healthy individuals and leprosy patients. Eur. J. Immunol. 20:2651-2659.
194. Kang, T. J., and G. T. Chae. 2001. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31:53-58.
195. Kang, T. J., S. K. Kim, S. B. Lee, G. T. Chae, and J. P. Kim. 2003. Comparison of two different PCR amplification products (the 18-kDa protein gene vs. RLEP repetitive sequence) in the diagnosis of Mycobacterium leprae. Clin. Exp. Dermatol. 28:420-424.
196. Kang, T. J., S. B. Lee, and G. T. Chae. 2002. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20:56-62.
197. Kang, T. J., C. E. Yeum, B. C. Kim, E. Y. You, and G. T. Chae. 2004. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunol. 112:674-680.
198. Kaplan, G. 1993. Recent advances in cytokine therapy in leprosy. J. Infect. Dis. 167:518-22.
199. Kaplan, G., W. J. Britton, G. E. Hancock, W. J. Theuvenet, K. A. Smith, C. K. Job, P. W. Roche, A. Molloy, R. Burkhardt, J. Barker, et al. 1991. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J. Exp. Med. 173:993-1006.
200. Kaplan, G., R. Kiessling, S. Teklemariam, G. Hancock, G. Sheftel, C. K. Job, P. Converse, T. H. Ottenhoff, M. Becx-Bleumink, M. Dietz, and Z. A. Cohn. 1989. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J. Exp. Med. 169:893-907.
201. Kaplan, G., N. K. Mathur, C. K. Job, I. Nath, and Z. A. Cohn. 1989. Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc. Natl. Acad. Sci. USA 86:8073-8077.
202. Kaplan, G., G. Walsh, L. S. Guido, P. Meyn, R. A. Burkhardt, R. M. Abalos, J. Barker, P. A. Frindt, T. T. Fajardo, R. Celona, and Z. A. Cohn. 1992. Novel responses of human skin to intradermal recombinant granulocyte/ macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J. Exp. Med. 175:1717-1728.
203. Kar, B. R., and R. Babu. 2004. Methotrexate in resistant ENL. Int. J. Lepr. Other Mycobact. Dis. 72:480-482.
204. Karin, M. 1998. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487-490.
205. Karonga Prevention Trial Group. 1996. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348:17-24.
206. Kashala, O., R. Marlink, M. Ilunga, M. Diese, B. Gormus, K. Xu, P. Mukeba, K. Kasongo, and M. Essex. 1994. Infection with human immunodeficiency virus type 1 (HIV-1) and human T cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-1 cross-reactivity and antibodies to lipoarabinomannan. J. Infect. Dis. 169:296-304.
207. Katoch, K., V. M. Katoch, M. Natrajan, A. S. Bhatia, Sreevatsa, U. D. Gupta, V. D. Sharma, C. T. Shivannavar, M. A. Patil, and V. P. Bharadwaj. 1995. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Int. J. Lepr. Other Mycobact. Dis. 63:202-212.
208. Katoch, V. M. 1981. A report on the biochemical analysis of Mycobacterium w. Lepr. India 53:385-389.
209. Katoch, V. M. 1999. Molecular techniques for leprosy: present applications and future perspectives. Indian J. Lepr. 71:45-59.
210. Khanolkar, V. R. 1964. Pathology of leprosy, p. 125-151. In R. G. Cochrane and T. F. Davey (ed.), Leprosy in theory and practice. John Wright and Sons, Ltd., Bristol, United Kingdom.
211. Khanolkar-Young, S., D. Snowdon, and D. N. J. Lockwoood. 1998. Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-B) in leprosy lesions. Clin. Exp. Immunol. 113:438-442.
212. Kiani, A., A. Rao, and J. Aramburu. 2000. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12:359-372.
213. Kimura, H., Y. Maeda, F. Takeshita, L. E. Takaoka, M. Matsuoka, and M. Makino. 2004. Upregulation of T-cell-stimulating activity of mycobacteria-infected macrophages. Scand. J. Immunol. 60:278-286.
214. Kirchheimer, W. F., and R. M. Sanchez. 1973. Leprosy-susceptibility testing of armadillos. 2. Late cell and bacterial responses at inoculation site of living leprosy bacilli in 'resistant' armadillos. Microbios 8:241-246.
215. Kirchheimer, W. F., and R. M. Sanchez. 1981. Intraspecies differences of resistance against leprosy in nine-banded armadillos. Lepr. India 53:525-530.
216. Kirchheimer, W. F., R. M. Sanchez, and E. J. Shannon. 1978. Effect of specific vaccine on cell-mediated immunity of armadillos against M. leprae. Int. J. Lepr. Other Mycobact. Dis. 46:353-357.
217. Kirchheimer, W. F., and E. E. Storrs. 1971. Attempts to establish the armadillo (Dasypus novemcinctus Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo. Int. J. Lepr. Other Mycobact. Dis. 39:693-702.
218. Kirchheimer, W. F., E. E. Storrs, and C. H. Binford. 1972. Attempts to establish the armadillo (Dasypus novemcinctus linn.) as a model for the study of leprosy. II. Histopathologic and bacteriologic post-mortem findings in lepromatoid leprosy in the armadillo. Int. J. Lepr. Other Mycobact. Dis. 40:229-242.
219. Kirkaldy, A. A., A. C. Musonda, S. Khanolkhar-Young, S. Suneetha, and D. N. Lockwood. 2003. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin. Exp. Immunol. 134:447-453.
220. Kissenpfennig, A., S. Ait-Yahia, V. Clair-Moninot, H. Stossel, E. Badell, Y. Bordat, J. L. Pooley, T. Lang, E. Prina, I. Coste, O. Gresser, T. Renno, N. Winter, G. Milon, K. Shortman, N. Romani, S. Lebecque, B. Malissen, S. Saeland, and P. Douillard. 2005. Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol. Cell. Biol. 25:88-99.
221. Koppel, E. A., I. S. Ludwig, M. S. Hernandez, T. L. Lowary, R. R. Gadikota, A. B. Tuzikov, C. M. Vandenbroucke-Grauls, Y. van Kooyk, B. J. Appelmelk, and T. B. Geijtenbeek. 2004. Identification of the mycobacterial carbohydrate structure that binds the C-type lectins DC-SIGN, L-SIGN and SIGNR1. Immunobiology 209:117-127.
222. Krahenbuhl, J. L., and L. B. Adams. 1999. Mycobacterium leprae as an opportunistic pathogen, p. 75-90. In L. J. Paradise (ed.), Opportunistic intracellular bacteria and immunity. Plenum Press, New York, N.Y.
223. Krahenbuhl, J. L., and L. B. Adams. 2000. Exploitation of gene knockout mice models to study the pathogenesis of leprosy. Lepr. Rev. 71:5170-5175.
224. Krutzik, S. R., M. T. Ochoa, P. A. Sieling, S. Uematsu, Y. W. Ng, A. Legaspi, P. T. Liu, S. T. Cole, P. J. Godowski, Y. Maeda, E. N. Sarno, M. V. Norgard, P. J. Brennan, S. Akira, T. H. Rea, and R. L. Modlin. 2003. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat. Med. 9:525-532.
225. Krutzik, S. R., B. Tan, H. Li, M. T. Ochoa, P. T. Liu, S. E. Sharfstein, T. G. Graeber, P. A. Sieling, Y. J. Liu, T. H. Rea, B. R. Bloom, and R. L. Modlin. 2005. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11:653-660.
226. Kulkarni, V. M., and J. K. Seydel. 1983. Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from Mycobacterium lufu and Mycobacterium leprae. A comparison. Chemotherapy 29:58-67.
227. Kumar, B., S. Dogra, and I. Kaur. 2004. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int. J. Lepr. Other Mycobact. Dis. 72:125-133.
228. Kuper, S. W. A. 1964. The lepromin reaction, p. 183-189. In R. G. Cochrane and T. F. Davey (ed.), Leprosy in theory and practice. John Wright and Sons, Ltd., Bristol, United Kingdom.
229. Kurabachew, M., A. Wondimu, and J. J. Ryon. 1998. Reverse transcription-PCR detection of Mycobacterium leprae in clinical specimens. J. Clin. Microbiol. 36:1352-1356.
230. Lahiri, R., B. Randhawa, and J. Krahenbuhl. 2005. Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J. Med. Microbiol. 54:235-242.
231. Lawn, S. D., C. Wood, and D. N. Lockwood. 2003. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin. Infect. Dis. 36:e5-6.
232. Lehman, L. F., M. B. Orsini, and A. R. Nicholl. 1993. The development and adaptation of the Semmes-Weinstein monofilaments in Brazil. J. Hand Ther. 6:290-297.
233. Levy, L., C. C. Shepard, and P. Fasal. 1976. The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. Int. J. Lepr. Other Mycobact. Dis. 44:183-187.
234. Little, D., S. Khanolkar-Young, Coulthart, A. S. Suneetha, and D. N. J. Lockwood. 2001. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect. Immun. 69:3413-3417.
235. Lockwood, D. 2004. Leprosy. Clin. Evid. 10:1103-1114.
236. Lockwood, D. N. 1996. The management of erythema nodosum leprosum: current and future options. Lepr. Rev. 67:253-259.
237. Lockwood, D. N., and H. H. Sinha. 1999. Pregnancy and leprosy: a comprehensive literature review. Int. J. Lepr. Other Mycobact. Dis. 67:6-12.
238. Lockwood, D. N., and S. Suneetha. 2005. Leprosy: too complex a disease for a simple elimination paradigm. Bull. W. H. O. 83:230-235.
239. Lucas, S. 1993. Human immunodeficiency virus and leprosy. Lepr. Rev. 64:97-103.
240. Lumpkin, L. R., III, G. F. Cox, and J. E. Wolf, Jr. 1983. Leprosy in five armadillo handlers. J. Am. Acad. Dermatol. 9:899-903.
241. Lwin, K., T. Sundaresan, M. M. Gyi, L. M. Bechelli, C. Tamondong, P. G. Garbajosa, H. Sansarricq, and S. K. Noordeen. 1985. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull. W. H. O. 63:1069-1078.
242. Maeda, S., M. Matsuoka, N. Nakata, M. Kai, Y. Maeda, K. Hashimoto, H. Kimura, K. Kobayashi, and Y. Kashiwabara. 2001. Multidrug-resistant Mycobacterium leprae from patients with leprosy. Antimicrob. Agents Chemother. 45:3635-3639.
243. Maeda, Y., M. Gidoh, N. Ishii, C. Mukai, and M. Makino. 2003. Assessment of cell mediated immunogenicity of Mycobacterium leprae-derived antigens. Cell. Immunol. 222:69-77.
244. Mahajan, V. K., N. L. Sharma, R. C. Sharma, and A. Sharma. 2003. Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr. Rev. 74:171-174.
245. Mak, T. W., J. M. Penninger, and P. S. Ohashi. 2001. Knockout mice: a paradigm shift in modern immunology. Nat. Rev. Immunol. 1:11-19.
246. Manandhar, R., N. Shrestha, C. R. Butlin, and P. W. Roche. 2002. High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin. Exp. Immunol. 128:333-338.
247. Marlowe, S. N., R. A. Hawksworth, C. R. Butlin, P. G. Nicholls, and D. N. Lockwood. 2004. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans. R. Soc. Trop. Med. Hyg. 98:602-609.
248. Marques, M. A., V. L. Antonio, E. N. Sarno, P. J. Brennan, and M. C. Pessolani. 2001. Binding of alpha2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. J. Med. Microbiol. 50:23-28.
249. Marques, M. A., B. J. Espinosa, E. K. Xavier da Silveira, M. C. Pessolani, A. Chapeaurouge, J. Perales, K. M. Dobos, J. T. Belisle, J. S. Spencer, and P. J. Brennan. 2004. Continued proteomic analysis of Mycobacterium leprae subcellular fractions. Proteomics 4:2942-2953.
250. Marquet, S., and E. Schurr. 2001. Genetics of susceptibility to infectious diseases: tuberculosis and leprosy as examples. Drug Metab. Dispos. 29:479-483.
251. Mascarell, L., and P. Truffa-Bachi. 2003. New aspects of cyclosporin a mode of action: from gene silencing to gene up-regulation. Mini Rev. Med. Chem. 3:205-214.
252. Matsuoka, M., Y. Kashiwabara, and M. Namisato. 2000. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int. J. Lepr. Other Mycobact. Dis. 68:452-455.
253. Matsuoka, M., S. Maeda, M. Kai, N. Nakata, G. T. Chae, T. P. Gillis, K. Kobayashi, S. Izumi, and Y. Kashiwabara. 2000. Mycobacterium leprae typing by genomic diversity and global distribution of genotypes. Int. J. Lepr. Other Mycobact. Dis. 68:121-128.
254. McMurry, J., H. Sbai, M. L. Gennaro, E. J. Carter, W. Martin, and A. S. De Groot. 2005. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinburgh) 85:95-105.
255. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69:681-686.
256. Mehra, V., B. R. Bloom, A. C. Bajardi, C. L. Grisso, P. A. Sieling, D. Alland, J. Convit, X. D. Fan, S. W. Hunter, P. J. Brennan, et al. 1992. A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J. Exp. Med. 175:275-284.
257. Mehta, V. R. 1996. Leprosy resistant to multi-drug-therapy (MDT) successfully treated with ampicillin-sulbactam combination-a case report. Indian J. Med. Sci. 50:305-307.
258. Meier, A., L. Heifets, R. J. Wallace, Jr., Y. Zhang, B. A. Brown, P. Sander, and E. C. Bottger. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of muMeimaltiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174:354-360.
259. Meima, A., P. R. Saunderson, S. Gebre, K. Desta, and J. D. Habbema. 2001. Dynamics of impairment during and after treatment: the AMFES cohort. Lepr. Rev. 72:158-170.
260. Meima, A., W. C. Smith, G. J. van Oortmarssen, J. H. Richardus, and J. D. Habbema. 2004. The future incidence of leprosy: a scenario analysis. Bull. W. H. O. 82:373-380.
261. Miller, R. A., J. Y. Shen, T. H. Rea, and J. P. Harnisch. 1987. Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Int. J. Lepr. Other Mycobact. Dis. 55:441-449.
262. Reference deleted.
263. Mira, M. T., A. Alcais, V. T. Nguyen, M. O. Moraes, C. Di Flumeri, H. T. Vu, C. P. Mai, T. H. Nguyen, N. B. Nguyen, X. K. Pham, E. N. Sarno, A. Alter, A. Montpetit, M. E. Moraes, J. R. Moraes, C. Dore, C. J. Gallant, P. Lepage, A. Verner, E. Van De Vosse, T. J. Hudson, L. Abel, and E. Schurr. 2004. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427:636-640.
264. Misra, N., A. Murtaza, B. Walker, N. P. Narayan, R. S. Misra, V. Ramesh, S. Singh, M. J. Colston, and I. Nath. 1995. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Immunology 86:97-103.
265. Mistry, Y., D. B. Young, and R. Mukherjee. 1992. hsp70 synthesis in Schwann cells in response to heat shock and infection with Mycobacterium leprae. Infect. Immun. 60:3105-3110.
266. Mittal, A., R. S. Mishra, and I. Nath. 1989. Accessory cell heterogeneity in lepromatous leprosy: dendritic cells and not monocytes support T cell responses. Clin. Exp. Immunol. 76:233-239.
267. Modi, K., M. Mancini, and M. P. Joyce. 2003. Lepromatous leprosy in a heart transplant recipient. Am. J. Transplant. 3:1600-1603.
268. Modlin, R. L., J. F. Gebhard, C. R. Taylor, and T. H. Rea. 1983. In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Clin. Exp. Immunol. 53:17-24.
269. Modlin, R. L., F. M. Hofman, C. R. Taylor, and T. H. Rea. 1983. T lymphocyte subsets in the skin lesions of patients with leprosy. J. Am. Acad. Dermatol. 8:182-189.
270. Modlin, R. L., J. Melancon-Kaplan, S. M. M. Young, C. Pirmez, H. Kino, J. Convit, T. H. Rea, and B. R. Bloom. 1988. Learning from lesions: patterns of tissue inflammation in leprosy. Proc. Natl. Acad. Sci. USA 85:1213-1217.
271. Modlin, R., and T. Rea. 1994. Immunopathology of leprosy, p. 225-234. In R. C. Hastings and D. V. A. Opromolla (ed.), Leprosy. Churchill Livingstone, New York, N.Y.
272. Mollenkopf, H. J., L. Grode, J. Mattow, M. Stein, P. Mann, B. Knapp, J. Ulmer, and S. H. Kaufmann. 2004. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72:6471-6479.
273. Monot, M., N. Honore, T. Gamier, R. Araoz, J. Y. Coppee, C. Lacroix, S. Sow, J. S. Spencer, R. W. Truman, D. L. Williams, R. Gelber, M. Virmond, B. Flageul, S. N. Cho, B. Ji, A. Paniz-Mondolfi, J. Convit, S. Young, P. E. Fine, V. Rasolofo, P. J. Brennan, and S. T. Cole. 2005. On the origin of leprosy. Science 308:1040-1042.
274. Moraes, M. O., N. C. Duppre, P. N. Suffys, A. R. Santos, A. S. Almeida, J. A. Nery, E. P. Sampaio, and E. N. Sarno. 2001. Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics 53:45-47.
275. Moraes, M. O., E. N. Sarno, A. S. Almeida, B. C. Saraiva, J. A. Nery, R. C. Martins, and E. P. Sampaio. 1999. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand. J. Immunol. 50:541-549.
276. Moraes, M. O., E. N. Sarno, R. M. Teles, A. S. Almeida, B. C. Saraiva, J. A. Nery, and E. P. Sampaio. 2000. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J. Investig. Dermatol. 115:935-941.
277. Moreira, A. L., G. Kaplan, L. G. Villahermosa, T. J. Fajardo, R. M. Abalos, R. V. Cellona, M. V. Balagon, E. V. Tan, and G. P. Walsh. 1998. Comparison of pentoxifylline, thalidomide and prednisone in the treament of ENL. Int. J. Lepr. Other Mycobact. Dis. 66:61-65.
278. Moschella, S. L. 2004. An update on the diagnosis and treatment of leprosy. J. Am. Acad. Dermatol. 51:417-426.
279. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 146:2348-2357.
280. Mueller, D. L. 2004. E3 ubiquitin ligases as T cell anergy factors. Nat. Immunol. 5:883-890.
281. Mukherjee, R., and N. H. Antia. 1986. Host-parasite interrelationship between M. leprae and Schwann cells in vitro. Int. J. Lepr. Other Mycobact. Dis. 54:632-638.
282. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
283. Mutis, T., E. M. Kraakman, Y. E. Cornelisse, J. B. Haanen, H. Spits, R. R. De Vries, and T. H. Ottenhoff. 1993. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. J. Immunol. 150:4641-4651.
284. Naafs, B. 1996. Bangkok Workshop on Leprosy Research: treatment of reactions and nerve damage. Int. J. Lepr. Other Mycobact. Dis. 64:521-28.
285. Naafs, B. 2003. Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr. Rev. 74:328-336.
286. Nath, I., N. Vemuri, A. L. Reddi, M. Bharadwaj, P. Brooks, M. J. Colston, R. S. Misra, and V. Ramesh. 2000. Dysregulation of IL-4 expression in lepromatous leprosy patients with and without erythema nodosum leprosum. Lepr. Rev. 71(Suppl.):S130-137.
287. Nath, I., N. Vemuri, A. L. Reddi, S. Jain, P. Brooks, M. J. Colston, R. S. Misra, and V. Ramesh. 2000. The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients. Immunol. Lett. 75:69-76.
288. Nelson, K. E. 2005. Leprosy and HIV infection (rarely the twain shall meet?). Int. J. Lepr. Other Mycobact. Dis. 73:131-133.
289. Nery, J. A., A. R. Perisse, A. M. Sales, L. M. Vieira, R. V. Souza, E. P. Sampaio, and E. N. Sarno. 2000. The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J. Lepr. 72:457-467.
290. Ng, V., G. Zanazzi, R. Timpl, J. Tails, J. L. Salzer, P. J. Brennan, and A. Rambukkana. 2000. Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. Cell 103:511-529.
291. Ngamying, M., P. Sawanpanyalert, R. Butraporn, J. Nikasri, S. N. Cho, L. Levy, and P. J. Brennan. 2003. Effect of vaccination with refined components of the organism on infection of mice with Mycobacterium leprae. Infect. Immun. 71:1596-1598.
292. Nigou, J., C. Zelle-Rieser, M. Gilleron, M. Thurnher, and G. Puzo. 2001. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. 166:7477-8485.
293. Nogueira, N., G. Kaplan, E. Levy, E. N. Sarno, P. Kushner, A. Granelli-Piperno, L. Vieira, V. Colomer Gould, W. Levis, R. Steinman, et al. 1983. Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J. Exp. Med. 158:2165-2170.
294. Norman, G., G. Joseph, and J. Richard. 2004. Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years. Int. J. Lepr. Other Mycobact. Dis. 72:1-7.
295. Ochoa, M. T., S. Stenger, P. A. Sieling, S. Thoma-Uszynski, S. Sabet, S. Cho, A. M. Krensky, M. Rollinghoff, E. Nunes Sarno, A. E. Burdick, T. H. Rea, and R. L. Modlin. 2001. T-cell release of granulysin contributes to host defense in leprosy. Nat. Med. 7:174-179.
296. Oliveira, R. B., M. T. Ochoa, P. A. Sieling, T. H. Rea, A. Rambukkana, E. N. Sarno, and R. L. Modlin. 2003. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect. Immun. 71:1427-1433.
297. Ottenhoff, T. H. 2002. Mycobacterium leprae and demyelination. Science 297:1475-1476.
298. Ottenhoff, T. H., and R. R. de Vries. 1987. HLA class II immune response and suppression genes in leprosy. Int. J. Lepr. Other Mycobact. Dis. 55:521-534.
299. Pattyn, S. R., D. Ursi, M. Ieven, V. Raes, and P. Jamet. 1992. Polymerase chain reaction amplifying DNA coding for species-specific rRNA of Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis. 60:234-243.
300. Pereira, G. A., M. M. Stefani, J. A. Araujo Filho, L. C. Souza, G. P. Stefani, and C. M. Martelli. 2004. Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium leprae co-infection: HIV-1 subtypes and clinical, immunologic, and histopathologic profiles in a Brazilian cohort. Am. J. Trop. Med. Hyg. 71:679-684.
301. Petri, V., E. V. Mendes, and B. Beiguelman. 1985. Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 53:540-545.
302. Pignataro, P., S. Rocha Ada, J. A. Nery, A. Miranda, A. M. Sales, H. Ferrreira, V. Valentim, and P. N. Suffys. 2004. Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 23:408-411.
303. Plikaytis, B. B., R. H. Gelber, and T. M. Shinnick. 1990. Rapid and sensitive detection of Mycobacterium leprae using a nested-primer gene amplification assay. J. Clin. Microbiol. 28:1913-1917.
304. Ponnighaus, J. M., P. E. Fine, J. A. Sterne, R. J. Wilson, E. Msosa, P. J. Gruer, P. A. Jenkins, S. B. Lucas, N. G. Liomba, and L. Bliss. 1992. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339:636-639.
305. Ponnighaus, J. M., L. J. Mwanjasi, P. E. M. Fine, M.-A. Shaw, A. C. Turner, S. M. Oxborrow, S. B. Lucas, P. A. Jenkins, J. A. C. Sterne, and L. Bliss. 1991. Is HIV infection a risk factor for leprosy? Int. J. Lepr. 59:221-228.
306. Prigozy, T. I., P. A. Sieling, D. Clemens, P. L. Stewart, S. M. Behar, S. A. Porcelli, M. B. Brenner, R. L. Modlin, and M. Kronenberg. 1997. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Immunity 6:187-197.
307. Quismorio, F. P., Jr., T. Rea, S. Chandor, N. Levan, and G. J. Friou. 1978. Lucio's phenomenon: an immune complex deposition syndrome in lepromatous leprosy. Clin. Immunol. Immunopathol. 9:184-193.
308. Rajalingam, R., D. P. Singal, and N. K. Mehra. 1997. Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Tissue Antigens 49:168-172.
309. Ramasesh, N., L. B. Adams, S. G. Franzblau, and J. L. Krahenbuhl. 1991. Effects of activated macrophages on Mycobacterium leprae. Infect. Immun. 59:2864-2869.
310. Rambukkana, A. 2000. How does Mycobacterium leprae target the peripheral nervous system? Trends Microbiol. 8:23-28.
311. Rambukkana, A. 2004. Mycobacterium leprae-induced demyelination: a model for early nerve degeneration. Curr. Opin. Immunol. 16:511-518.
312. Rambukkana, A., J. L. Salzer, P. D. Yurchenco, and E. I. Tuomanen. 1997. Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin alpha 2 chain. Cell 88:811-821.
313. Rambukkana, A., G. Zanazzi, N. Tapinos, and J. L. Salzer. 2002. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 296:927-931.
314. Ramu, G. 1998. Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosy lesions. Lepr. Rev. 69:78-82.
315. Randive, K. J., C. V. Bapat, and V. R. Khanolkar. 1962. Studies of pathogenicity of the ICRC bacillus isolated from human lepromatous leprosy. Int. J. Lepr. 30:442-456.
316. Reddy, V. M., J. F. O'Sullivan, and P. R. Gangadharam. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623.
317. Rees, R. J. W., M. F. R. Waters, A. G. M. Weddell, and E. Palmer. 1967. Experimental lepromatous leprosy. Nature 215:599-602.
318. Rees, R. J. 1973. A century of progress in experimental leprosy. Int. J. Lepr. Other Mycobact. Dis. 41:320-328.
319. Richardus, J. H., P. G. Nicholls, R. P. Croft, S. G. Withington, and W. C. Smith. 2004. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int. J. Epidemiol. 33:337-343.
320. Richey, D. P., and G. M. Brown. 1969. The biosynthesis of folic acid. IX. Purification and properties of the enzymes required for the formation of dihydropteroic acid. J. Biol. Chem. 244:1582-1592.
321. Richter, E., M. Duchrow, C. Schluter, M. Hahn, H. D. Flad, and J. Gerdes. 1994. Detection of Mycobacterium leprae by three-primer PCR. Immunobiology 191:351-353.
322. Ridley, D. S., and W. H. Jopling. 1966. Classification of leprosy according to immunity-a five-group system. Int. J. Lepr. Other Mycobact. Dis. 34:255-273.
323. Ridley, D. S., and K. B. Radia. 1981. The histological course of reactions in borderline leprosy and their outcome. Int. J. Lepr. Other Mycobact. Dis. 49:383-392.
324. Rieneck, K., M. Diamant, P. M. Haahr, M. Schonharting, and K. Bendtzen. 1993. In vitro immunomodulatory effects of pentoxifylline. Immunol. Lett. 37:131-138.
325. Rojas, R. E., S. O. Demichelis, E. N. Sarno, and A. Segal-Eiras. 1997. IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. FEMS Immunol. Med. Microbiol. 19:65-74.
326. Rook, G. A. 1988. The role of vitamin D in tuberculosis. Am. Rev. Respir. Dis. 138:768-770.
327. Rosat, J. P., E. P. Grant, E. M. Beckman, C. C. Dascher, P. A. Sieling, D. Frederique, R. L. Modlin, S. A. Porcelli, S. T. Furlong, and M. B. Brenner. 1999. CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ ab T-cell pool. J. Immunol. 162:366-371.
328. Roy, S., A. Frodsham, B. Saha, S. K. Hazra, C. G. N. Mascie-Taylor, and A. V. S. Hill. 1999. Association of vitamin D receptor genotype with leprosy type. J. Infect. Dis. 179:187-191.
329. Roy, S., W. McGuire, C. G. N. Mascie-Taylor, S. Hazra, A. V. S. Hill, and D. Kwiatkowski. 1997. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J. Infect. Dis. 176:530-532.
330. Sabin, T. D., T. R. Swift, and R. R. Jacobson. 1993. Leprosy, p. 1354-1379. In P. J. Dyck and P. K. Thomas (ed.), Peripheral neuropathy. W. B. Saunders, Philadelphia, Pa.
331. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-282.
332. Sampaio, E. P., J. R. T. Caneshi, J. A. C. Nery, N. C. Duppre, G. M. B. Pereira, L. M. M. Vieira, A. L. Moreira, G. Kaplan, and E. N. Sarno. 1995. Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. Infect. Immun. 63:1848-1854.
333. Sampaio, E. P., G. Kaplan, A. Miranda, J. A. Nery, C. P. Miguel, S. M. Viana, and E. N. Sarno. 1993. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408-414.
334. Sampaio, E. P., M. O. Moraes, J. A. Nery, A. R. Santos, H. C. Matos, and E. N. Sarno. 1998. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin. Exp. Immunol. 111:300-308.
335. Sampaio, E. P., A. L. Moreira, E. N. Sarno, A. M. Malta, and G. Kaplan. 1992. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. 175:1729-1737.
336. Sampaio, E. P., E. N. Sarno, R. Galilly, Z. A. Conh, and G. Kaplan. 1991. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173:699-703.
337. Santos, A. R., V. Balassiano, M. L. Oliveira, M. A. Pereira, P. B. Santos, W. M. Degrade, and P. N. Suffys. 2001. Detection of Mycobacterium leprae DNA by polymerase chain reaction in the blood of individuals, eight years after completion of anti-leprosy therapy. Mem. Inst. Oswaldo Cruz 96:1129-1133.
338. Santos, A. R., P. N. Suffys, P. R. Vanderborght, M. O. Moraes, L. M. Vieira, P. H. Cabello, A. M. Bakker, H. J. Matos, T. W. Huizinga, T. H. Ottenhoff. E. P. Sampaio, and E. N. Sarno. 2002. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J. Infect. Dis. 186:1687-1691.
339. Santos, D. O., S. L. Santos, D. Esquenazi, J. A. Nery, M. Defruyt, K. Lorre, and H. van Heuverswyn. 2001. Evaluation of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules and dendritic cells on the immune response in leprosy. Nihon Hansenbyo Gakkai Zasshi 70:15-24.
340. Sarno, E. N., G. E. Grau, L. M. M. Vieira, and J. A. Nery. 1991. Serum levels of tumour necrosis factor-alpha and interleukin-1B during leprosy reactional states. Clin. Exp. Immunol. 84:103-108.
341. Sathish, M., R. E. Esser, J. E. Thole, and J. E. Clark-Curtiss. 1990. Identification and characterization of antigenic determinants of Mycobacterium leprae that react with antibodies in sera of leprosy patients. Infect. Immun. 58:1327-1336.
342. Saunderson, P., S. Gebre, K. Desta, P. Byass, and D. N. Lockwood. 2000. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr. Rev. 71:285-308.
343. Save, M. P., V. P. Shetty, K. T. Shetty, and N. H. Antia. 2004. Alterations in neurofilament protein(s) in human leprous nerves: morphology, immunohistochemistry and Western immunoblot correlative study. Neuropathol. Appl. Neurobiol. 30:635-650.
344. Schleimer, R. P. 1993. An overview of glucocorticoid anti-inflammatory actions. Eur. J. Clin. Pharmacol. 45(Suppl. 1):S3-S7; discussion, S43-S44.
345. Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150:2920-2930.
346. Schlesinger, L. S., and M. A. Horwitz. 1991. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J. Exp. Med. 174:1031-1038.
347. Schon, T., N. Gebre, T. Sundqvist, H. S. Habetmariam, T. Engeda, and S. Britton. 1999. Increased levels of nitric oxide metabolites in urine from leprosy patients in reversal reaction. Lepr. Rev. 70:52-55.
348. Schon, T., R. H. Hernandez-Pando, Y. Negesse, R. Leekassa, T. Sundzvist, and S. Britton. 2001. Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions. Br. J. Dermatol. 145:809-815.
349. Schon, T., R. Leekassa, N. Gebre, T. Sundqvist, E. Bizuneh, and S. Britton. 2000. High dose prednisolone treatment of leprosy patients undergoing reactions is associated with a rapid decrease in urinary nitric oxide metabolites and clinical improvement. Lepr. Rev. 71:355-362.
350. Scollard, D. M. 2000. Endothelial cells and the pathogenesis of lepromatous neuritis: insights from the armadillo model. Microbes Infect. 2:1835-1843.
351. Scollard, D. M., T. P. Gillis, and D. L. Williams. 1998. Polymerase chain reaction assay for the detection and identification of Mycobacterium leprae in patients in the United States. Am. J. Clin. Pathol. 109:642-646.
352. Scollard, D. M., and M. P. Joyce. 2003. Leprosy (Hansen's disease), p. 101-106. In R. E. Rakel and E. T. Bope (ed.), Conn's current therapy. Elsevier Science, St. Louis, Mo.
353. Scollard, D. M., G. W. Lathrop, and R. W. Truman. 1996. Infection of distal peripheral nerves by M. leprae in infected armadillos; an experimental model of nerve involvement in leprosy. Int. J. Lepr. Other Mycobact. Dis. 64:146-151.
354. Scollard, D. M., G. McCormick, and J. Allen. 1999. Localization of Mycobacterium leprae to endothelial cells of epineural and perineural blood vessels and lymphatics. Am. J. Pathol. 154:1611-1620.
355. Scollard, D. M., T. Smith, L. Bhoopat, C. Theetranont, S. Rangdaeng, and D. M. Morens. 1994. Epidemiologic characteristics of leprosy reactions. Int. J. Lepr. Other Mycobact. Dis. 62:559-567.
356. Scollard, D. M., V. Suriyanon, L. Bhoopat, D. K. Wagner, T. C. Smith, K. Thamprasert, D. L. Nelson, and C. Theetranont. 1990. Studies of human leprosy lesions in situ using suction-induced blisters. 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Int. J. Lepr. Other Mycobact. Dis. 58:469-479.
357. Scollard, D. M., and D. L. Williams. 2002. Nerve injury in leprosy. UpToDate. [Online.] http://www.uptodate.com.
358. Scollard, D. M. 2005. Leprosy research declines, but most of the basic questions remain unanswered. Int. J. Lepr. Other Mycobact. Dis. 73:25-27.
359. 355a. Scollard, D. M., M. P. Joyce, and T. P. Gillis. Development of leprosy and type 1 leprosy reactions after treatment with Infliximab: a report of two cases. Clin. Infect. Dis., in press.
360. Sela, S., and J. E. Clark-Curtiss. 1991. Cloning and characterization of the Mycobacterium leprae putative ribosomal RNA promoter in Escherichia coli. Gene 98:123-127.
361. Sengupta, U. 1991. Studies on lepromin and soluble antigens of M. leprae: their classification standardization and use. Indian J. Lepr. 63:457-465.
362. Sergeantson, S. 1983. HLA and susceptibility to leprosy. Immunol. Rev. 70:89-112.
363. Seydel, J. K., M. Richter, and E. Wempe. 1980. Mechanism of action of the folate blocker diaminodiphenylsulfone (dapsone, DDS) studied in E. coli cell-free enzyme extracts in comparison to sulfonamides (SA). Int. J. Lepr. Other Mycobact. Dis. 48:18-29.
364. Shannon, E., and F. Sandoval. 1996. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol. Immunotoxicol. 18:59-72.
365. Shannon, E. J., R. O. Miranda, M. J. Morales, and R. C. Hastings. 1981. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol. 13:553-562.
366. Shannon, E. J., and F. Sandoval. 1995. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31:109-116.
367. Shepard, C. C. 1960. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice. J. Exp. Med. 112:445-454.
368. Shepard, C. C., and Y. T. Chang. 1962. Effect of several anti-leprosy drugs on multiplication of human leprosy bacilli in footpads of mice. Proc. Soc. Exp. Biol. Med. 109:636-638.
369. Shepard, C. C., R. J. Rees, L. Levy, S. R. Pattyn, J. Baohong, and E. C. Dela Cruz. 1986. Susceptibility of strains of Mycobacterium leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 54:11-15.
370. Shepard, C. C., L. L. Walker, and R. Van Landingham. 1978. Heat stability of Mycobacterium leprae immunogenicity. Infect. Immun. 22:87-93.
371. Sheskin, J. 1965. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6:303-306.
372. Shetty, V. P., M. W. Uplekar, and N. H. Antia. 1996. Primary resistance to single and multiple drugs in leprosy-a mouse footpad study. Lepr. Rev. 67:280-286.
373. Shi, L., R. P. Kraut, R. Aebersold, and A. H. Greenberg. 1992. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J. Exp. Med. 175:553-566.
374. Shimoji, Y., V. Ng, K. Matsumura, V. A. Fischetti, and A. Rambukkana. 1999. A 21 kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proc. Natl. Acad. Sci. USA 96:9857-9862.
375. Shin, Y. C., H. Lee, H. Lee, G. P. Walsh, J. D. Kim, and S. N. Cho. 2000. Variable numbers of TTC repeats in Mycobacterium leprae DNA from leprosy patients and use in strain differentiation. J. Clin. Microbiol. 38:4535-4538.
376. ShivRaj, L., S. A. Patil, A. Girdhar, U. Sengupta, K. V. Desikan, and H. Srinivasan. 1988. Antibodies to HIV-1 in sera from patients with mycobacterial infections. Int. J. Lepr. Other Mycobact. Dis. 56:546-551.
377. Sibley, L. D., S. G. Franzblau, and J. L. Krahenbuhl. 1987. Intracellular fate of Mycobacterium leprae in normal and activated mouse macrophages. Infect. Immun. 55:680-685.
378. Sibley, L. D., and J. L. Krahenbuhl. 1987. Mycobacterium leprae-burdened macrophages are refractory to activation by gamma interferon. Infect. Immun. 55:446-450.
379. Sibley, L. D., and J. L. Krahenbuhl. 1988. Defective activation of granuloma macrophages from Mycobacterium leprae-infected nude mice. J. Leukoc. Biol. 43:60-66.
380. Sibley, L. D., and J. L. Krahenbuhl. 1988. Induction of unresponsiveness to gamma interferon in macrophages infected with Mycobacterium leprae. Infect. Immun. 56:1912-1919.
381. Siddiqui, M. R., S. Meisner, K. Tosh, K. Balakrishnan, S. Ghei, S. E. Fisher, M. Golding, N. P. Shanker Narayan, T. Sitaraman, U. Sengupta, R. Pitchappan, and A. V. Hill. 2001. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat. Genet. 27:439-441.
382. Sieling, P. A., D. Chatterjee, S. A. Porcelli, T. I. Prigozy, R. J. Mazzaccaro, T. Soriano, B. R. Bloom, M. B. Brenner, M. Kronenberg, P. J. Brennan, and R. L. Modlin. 1995. CD-1-restricted T cell recognition of microbial lipoglycan antigens. Science 269:227-230.
383. Sieling, P. A., D. Jullien, M. Dahlem, T. F. Tedder, T. H. Rea, R. L. Modlin, and S. A. Procelli. 1999. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J. Immunol. 162:1851-1858.
384. Sieling, P. A., and R. L. Modlin. 1994. Cytokine patterns at the site of mycobacterial infection. Immunopharmacology 191:378-387.
385. Sieling, P. A., X. H. Wang, M. K. Gately, J. L. Oliveros, T. McHugh, P. F. Barnes, S. F. Wolf, L. Golkar, M. Yamamura, and Y. Yogi. 1994. IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153:3639-3647.
386. Singh, N., T. J. Birdi, S. Chandrashekar, and N. H. Antia. 1997. Schwann cell extracellular matrix protein production is modulated by Mycobacterium leprae and macrophage secretory products. J. Neurol. Sci. 151:13-22.
387. Skamene, E., P. Gros, A. Forget, P. A. Kongshavn, C. St. Charles, and B. A. Taylor. 1982. Genetic regulation of resistance to intracellular pathogens. Nature 297:506-509.
388. Skinsnes, O. K. 1964. The immunopathologic spectrum of leprosy, p. 152-182. In R. G. Cochrane and T. F. Davey (ed.), Leprosy in theory and practice. John Wright and Sons, Ltd., Bristol, United Kingdom.
389. Smith, W. C., A. M. Anderson, S. G. Withington, W. H. van Brakel, R. P. Croft, P. G. Nicholls, and J. H. Richardus. 2004. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). Br. Med. J. 328:1459.
390. Spencer, J. S., M. A. Marques, M. C. Lima, A. P. Junqueira-Kipnis, B. C. Gregory, R. W. Truman, and P. J. Brennan. 2002. Antigenic specificity of the Mycobacterium leprae homologue of ESAT-6. Infect. Immun. 70:1010-1013.
391. Spierings, E., T. De Boer, L. Zulianello, and T. H. Ottenhoff. 2000. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol. Cell Biol. 78:349-355.
392. Spies, T., M. Bresnahan, S. Bahrain, D. Arnold, G. Blanck, E. Mellins, D. Pious, and R. DeMars. 1990. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348:744-747.
393. Sreenivasan, P., R. S. Misra, D. Wilfred, and I. Nath. 1998. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Immunology 95:529-536.
394. Stanley, S. J., C. Howland, M. M. Stone, and I. Sutherland. 1981. BCG vaccination of children against leprosy in Uganda: final results. J. Hyg. (London) 87:233-248.
395. Stefani, M. M., C. M. Martelli, T. P. Gillis, and J. L. Krahenbuhl. 2003. In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J. Infect. Dis. 188:1024-1031.
396. Steinhofff, U., A. Wand-Wurttenberger, A. Bremerich, and S. H. E. Kaufmann. 1991. Mycobacterium leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Infect. Immun. 59:684-688.
397. Stenger, S., D. A. Hanson, R. Teitlebaum, P. Dewan, K. R. Niazi, C. J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Melian, C. Bogdan, S. A. Porcelli, B. R. Bloom, A. M. Krensky, and R. L. Modlin. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:121-125.
398. Storrs, E. E., and W. E. Greer. 1973. Maintenance and husbandry of armadillo colonies. Lab. Anim. Sci. 23:823-829.
399. Strieter, R. M., D. G. Remick, P. A. Ward, R. N. Spengler, J. P. Lynch III, J. Larrick, and S. L. Kunkel. 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230-1236.
400. Stump, P. R., R. Baccarelli, L. H. Marciano, J. R. Lauris, M. J. Teixeira, S. Ura, and M. C. Virmond. 2004. Neuropathic pain in leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 72:134-138.
401. Sugumaran, D. S. 1998. Leprosy reactions-complications of steroid therapy. Int. J. Lepr. Other Mycobact. Dis. 66:10-15.
402. Suneetha, L. M., D. Vardhini, S. Suneetha, A. S. Balasubramanian, C. K. Job, and D. Scollard. 2001. Biochemical aspects of Mycobacterium leprae binding proteins: a review of their role in pathogenesis. Int. J. Lepr. Other Mycobact. Dis. 69:341-348.
403. Swift, T. R. 1974. Peripheral nerve involvement in leprosy: quantitative histologic aspects. Acta Neuropathol. (Berlin) 29:1-8.
404. Tailleux, L., O. Schwartz, J. L. Herrmann, E. Pivert, M. Jackson, A. Amara, L. Legres, D. Dreher, L. P. Nicod, J. C. Gluckman, P. H. Lagrange, B. Gicquel, and O. Neyrolles. 2003. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197:121-127.
405. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
406. Taylor, D. E., and A. Chau. 1996. Tetracycline resistance mediated by ribosomal protection. Antimicrob. Agents Chemother. 40:1-5.
407. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
408. Teles, R. M., M. O. Moraes, N. T. Geraldo, A. M. Salles, E. N. Sarno, and E. P. Sampaio. 2002. Differential TNFalpha mRNA regulation detected in the epidermis of leprosy patients. Arch. Dermatol. Res. 294:355-362.
409. Teo, S. K., K. E. Resztak, M. A. Scheffler, K. A. Kook, J. B. Zeldis, D. I. Stirling, and S. D. Thomas. 2002. Thalidomide in the treatment of leprosy. Microbes Infect. 4:1193-1202.
410. Thangaraj, H. S., F. I. Lamb, E. O. Davis, P. J. Jenner, L. H. Jeyakumar, and M. J. Colston. 1990. Identification, sequencing, and expression of Mycobacterium leprae superoxide dismutase, a major antigen. Infect. Immun. 58:1937-1942.
411. Thole, J. E., B. Wieles, J. E. Clark-Curtiss, T. H. Ottenhoff, and T. F. Rinke de Wit. 1995. Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview. Mol. Microbiol. 18:791-800.
412. Thomas, D. A., J. S. Mines, T. M. Mack, D. C. Thomas, and T. H. Rea. 1987. Armadillo exposure among Mexican-born patients with lepromatous leprosy. J. Infect. Dis. 156:990-993.
413. Torres, P. J. J. Camarena, J. R. Gomez, J. M. Nogueira, V. Gimeno, J. C. Navarro, and A. Olmos. 2003. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts. Lepr. Rev. 74:18-30.
414. Tramontana, J. M., U. Utaipat, A. Molloy, P. Akarasewi, M. Burroughs, S. Makonkawkeyoon, B. Johnson, J. D. Klausner, W. Rom, and G. Kaplan. 1995. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1:384-397.
415. Tripathy, S. P. 1983. The case for B.C.G. Ann. Natl. Acad. Med. Sci. (India) 19:11-21.
416. Truman, R., A. B. Fontes, A. B. De Miranda, P. Suffys, and T. Gillis. 2004. Genotypic variation and stability of four variable-number tandem repeats and their suitability for discriminating strains of Mycobacterium leprae. J. Clin. Microbiol. 42:2558-2565.
417. Truman, R., and R. Sanchez. 1993. Armadillos: models for leprosy. Lab. Anim. 22:28-32.
418. Truman, R. W., and J. L. Krahenbuhl. 2001. Viable M. leprae as a research reagent. Int. J. Lepr. Other Mycobact. Dis. 69:1-12.
419. Truman, R. 2005. Leprosy in wild armadillos. Lepr. Rev. 76:198-208.
420. Tung, K. S., E. Umland, P. Matzner, K. Nelson, V. Schauf, L. Rubin, D. Wagner, D. Scollard, P. Vithayasai, V. Vithayasai, et al. 1987. Soluble serum interleukin 2 receptor levels in leprosy patients. Clin. Exp. Immunol. 69:10-15.
421. Underbill, D. M., A. Ozinsku, K. D. Smith, and A. Aderem. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signals in macrophages. Proc. Natl. Acad. Sci. USA 96:14459-14463.
422. Uyemura, K., J. F. Dixon, L. Wong, T. H. Rea, and R. L. Modlin. 1986. Effect of cyclosporine A in erythema nodosum leprosum. J. Immunol. 137:3620-3623.
423. Van Brakel, W. H., A. M. Anderson, S. G. Withington, R. P. Croft, P. G. Nicholls, J. H. Richardus, and W. C. Smith. 2003. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr. Rev. 74:300-310.
424. van de Vosse, E., M. A. Hoeve, and T. H. Ottenhoff. 2004. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect. Dis. 4:739-749.
425. van Gompel, A., E. van den Enden, and J. van den Ende. 1994. Cyclosporin A is not very effective in erythema nodosum leprosum (ENL). Trop. Geogr. Med. 46:331.
426. van Kooyk, Y., and T. B. Geijtenbeek. 2003. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3:697-709.
427. Verhagen, C. E., E. A. Wierenga, A. A. Buffing, M. A. Chand, W. R. Faber, and P. K. Das. 1997. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-study. J. Immunol. 159:4474-4483.
428. Vester, B., and S. Douthwaite. 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45:1-12.
429. Vissa, V. D., and P. J. Brennan. 2001. The genome of Mycobacterium leprae: a minimal mycobacterial gene set. Genome Biol. 2:1023.
430. Reference deleted.
431. Wagener, D. K., V. Schauf, K. E. Nelson, D. Scollard, A. Brown, and T. Smith. 1988. Segregation analysis of leprosy in families of northern Thailand. Genet. Epidemiol. 5:95-105.
432. Wallace, R. J., Jr., A. Meier, B. A. Brown, Y. Zhang, P. Sander, G. O. Onyi, and E. C. Bottger. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
433. Watts, C. 2004. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 5:685-692.
434. Weinberg, J. B. 1998. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol. Med. 4:557-591.
435. Wemambu, S. N., J. L. Turk, M. F. Waters, and R. J. Rees. 1969. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet ii:933-935.
436. Wheeler, P. R. 2001. The microbial physiologist's guide to the leprosy genome. Lepr. Rev. 72:399-407.
437. Wilkinson, R. J., and D. N. Lockwood. 2005. Antigenic trigger for type 1 reaction in leprosy. J. Infect. 50:242-243.
438. Williams, D. L., and T. P. Gillis. 2004. Molecular detection of drug resistance in Mycobacterium leprae. Lepr. Rev. 75:118-130.
439. Williams, D. L., T. P. Gillis, R. J. Booth, D. Looker, and J. D. Watson. 1990. The use of a specific DNA probe and polymerase chain reaction for the detection of Mycobacterium leprae. J. Infect. Dis. 162:193-200.
440. Williams, D. L., T. P. Gillis, and F. Portaels. 1990. Geographically distinct isolates of Mycobacterium leprae exhibit no genotypic diversity by restriction fragment-length polymorphism analysis. Mol. Microbiol. 4:1653-1659.
441. Williams, D. L., T. L. Pittman, T. P. Gillis, M. Matsuoka, and Y. Kashiwabara. 2001. Simultaneous detection of Mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis. J. Clin. Microbiol. 39:2083-2088.
442. Williams, D. L., L. Spring, T. P. Gillis, M. Salfinger, and D. H. Persing. 1998. Evaluation of a polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampin susceptibility of Mycobacterium tuberculosis from sputum specimens. Clin. Infect. Dis. 26:446-450.
443. Williams, D. L., L. Spring, E. Harris, P. Roche, and T. P. Gillis. 2000. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob. Agents Chemother. 44:1530-1537.
444. Williams, D. L., M. Torrero, P. R. Wheeler, R. W. Truman, M. Yoder, N. Morrison, W. R. Bishai, and T. P. Gillis. 2004. Biological implications of Mycobacterium leprae gene expression during infection. J. Mol. Microbiol. Biotechnol. 8:58-72.
445. Williams, D. L., C. Waguespack, K. Eisenach, J. T. Crawford, F. Portaels, M. Salfinger, C. M. Nolan, C. Abe, V. Sticht-Groh, and T. P. Gillis. 1994. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38:2380-2386.
446. Winter, N., J. A. Triccas, B. Rivoire, M. C. Pessolani, K. Eiglmeier, E. M. Lim, S. W. Hunter, P. J. Brennan, and W. J. Britton. 1995. Characterization of the gene encoding the immunodominant 35 kDa protein of Mycobacterium leprae. Mol. Microbiol. 16:865-876.
447. Woods, S. A., and S. T. Cole. 1990. A family of dispersed repeats in Mycobacterium leprae. Mol. Microbiol. 4:1745-1751.
448. World Health Organization. 1998. Leprosy. Wkly. Epidemiol. Rec. 73:153-160.
449. World Health Organization. 2004. Leprosy elimination project. Status report 2002-2003. World Health Organization, Geneva, Switzerland.
450. World Health Organization Expert Committee on Leprosy. 1977. Fifth report. World Health Organization, Geneva, Switzerland.
451. World Health Organization Study Group. 1982. Chemotherapy of leprosy for control programmes. World Health Organization, Geneva, Switzerland.
452. Yamamura, M., K. Uyemura, R. J. Deans, K. Weinberg, T. H. Rea, B. R. Bloom, and R. L. Modlin. 1991. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277-279.
453. Yamamura, M., X. H. Wang, J. D. Ohmen, K. Uyemura, T. H. Rea, B. R. Bloom, and R. L. Modlin. 1992. Cytokine patterns of immunologically mediated tissue damage. J. Immunol. 149:1470-1475.
454. You, E. Y., T. J. Kang, S. K. Kim, S. B. Lee, and G. T. Chae. 2005. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J. Infect. 50:6-11.
455. Yuasa, Y. 2003. Remarks by Damien Dutton Award Recipient Dr. Yo Yuasa. Int. J. Lepr. Other Mycobact. Infect. 71:33-35.
456. Zaheer, S. A., K. R. Beena, H. K. Kar, A. K. Sharma, R. S. Misra, A. Mukherjee, R. Mukherjee, H. Kaur, R. M. Pandey, R. Walia, et al. 1995. Addition of immunotherapy with Mycobacterium w vaccine to multi-drug therapy benefits multibacillary leprosy patients. Vaccine 13:1102-1110.
457. Zaheer, S. A., R. Mukherjee, B. Ramkumar, R. S. Misra, A. K. Sharma, H. K. Kar, H. Kaur, S. Nair, A. Mukherjee, and G. P. Talwar. 1993. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167:401-410.
458. Zhang, Y., J. Gao, K. K. Chung, H. Huang, V. L. Dawson, and T. M. Dawson. 2000. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97:13354-13359.
459. Zodpey, S. P., N. N. Ambadekar, and A Thakur. 2005. Effectiveness of bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health 119:209-216.